Fairvalue-Calculator Fairvalue-Calculator
EN DE

Nanjing Vishee Medical Technology Co (688580) Fair Value & Analysis

Healthcare · CN · Market cap 5.1B CNY

Price¥53.91
Fair Value¥31.39
Upside-41.8%
Quality95/100
Evidence: High Range ¥23.54 – ¥39.23

Analysis

Nanjing Vishee Medical Technology Co (688580) currently trades at ¥53.91, while our model-based Fair Value estimate is ¥31.39 — implying the stock looks roughly 41.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Nanjing Vishee Medical Technology Co., Ltd provides rehabilitation meditation products and solutions in China and internationally. The company offers MagNeuro, a transcranial magnetic stimulation (TMS) for use in anxiety disorders, movement disorders, and ADHD applications; MagNeuro ONE, a TMS therapy system with navigation for use in anxiety disorders applications; and MagBelle, a pelvic floor muscle stimulator for use in urinary incontinence, pelvic organ prolapse, chronic pelvic pain, vaginal laxity, and bowel dysfunction applications. It also provides MagGraver, a powered muscle stimulator for use in abdominal sculpting and body sculpting applications; RFIntima, a radiofrequency therapy product for use in pelvic floor dysfunction, genitourinary syndrome of menopause, and vulvar atrophy applications; and PicoV, a Nd:YAG picosecond laser system for use in pigmentary diseases, and tattoo removal and skin reconstruction applications. In addition, the company offers solutions to pelv…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -83% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.